Seres Therapeutics Inc To Discuss 109 ECOSPOR IV Study Results Call Transcript
Good day, and thank you for standing by. Welcome to the SER-109 ECOSPOR IV Study Results Conference Call.
(Operator Instructions)
Please be advised today's conference may be recorded.
(Operator Instructions).
I'd now like to hand the conference over to Dr. Carlo Tanzi of Investor Relations. Please go ahead.
Thank you, and good morning. A press release and accompanying slide presentation highlighting the positive SER-109 and ECOSPOR IV study results became available earlier this morning and can be found on the Investors & Media section of the company's website.
I'd like to remind you that we'll be making forward-looking statements relating to the timing of completion of the BLA filing, potential approval and commercial launch of SER-109, the marketing commercial opportunity for SER-109 and the potential for SER-109 to transform the treatment of CDI. Actual results may differ materially.
Additionally, these statements are subject to certain risks and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |